Recent Updates
Recently added Catalysts
Drug Modality Leaderboard
Top biotechs by clinical-trial depth in each drug modality. Counts include all upcoming trials (completion date ≥ 2026-02) from ClinicalTrials.gov.
Monoclonal antibody
2,188 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 |  AZNAstraZeneca PLC | 250 | 113 | $275.2B |
| 2 |  MRKMerck & Company, Inc. | 170 | 72 | $370.9B |
| 3 |  JNJJohnson & Johnson | 128 | 50 | $663.3B |
| 4 |  REGNRegeneron Pharmaceuticals, Inc. | 120 | 28 | $83.7B |
| 5 |  BMYBristol-Myers Squibb Company | 119 | 31 | $136.5B |
| 6 |  ABBVAbbVie Inc. | 104 | 27 | $453.1B |
| 7 |  NVSNovartis AG | 99 | 32 | $325.6B |
| 8 |  SNYSanofi | 96 | 22 | $106.9B |
| 9 |  LLYEli Lilly and Company | 78 | 35 | $1.1T |
| 10 |  AMGNAmgen Inc. | 76 | 27 | $236.4B |
Small molecule
1,481 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | AZNAstraZeneca PLC | 131 | 42 | $275.2B |
| 2 | NVSNovartis AG | 108 | 31 | $325.6B |
| 3 | ABBVAbbVie Inc. | 98 | 36 | $453.1B |
| 4 | MRKMerck & Company, Inc. | 91 | 34 | $370.9B |
| 5 | BMYBristol-Myers Squibb Company | 78 | 27 | $136.5B |
| 6 |  PFEPfizer, Inc. | 69 | 21 | $162.2B |
| 7 |  INCYIncyte Corporation | 68 | 14 | $25.7B |
| 8 | LLYEli Lilly and Company | 62 | 21 | $1.1T |
| 9 | JNJJohnson & Johnson | 50 | 18 | $663.3B |
| 10 |  EXELExelixis, Inc. | 45 | 6 | $14.6B |
Bispecific
422 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | JNJJohnson & Johnson | 54 | 14 | $663.3B |
| 2 | AZNAstraZeneca PLC | 47 | 19 | $275.2B |
| 3 | REGNRegeneron Pharmaceuticals, Inc. | 35 | 8 | $83.7B |
| 4 | AMGNAmgen Inc. | 32 | 8 | $236.4B |
| 5 |  GMABGenmab A/S | 26 | 6 | $21.0B |
| 6 |  GSKGSK plc | 23 | 8 | $100.9B |
| 7 |  DRTSAlpha Tau Medical Ltd. | 21 | — | $1.4B |
| 8 | PFEPfizer, Inc. | 19 | 5 | $162.2B |
| 9 | MRKMerck & Company, Inc. | 18 | 2 | $370.9B |
| 10 | INCYIncyte Corporation | 17 | 3 | $25.7B |
Vaccine
263 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | SNYSanofi | 41 | 11 | $106.9B |
| 2 | PFEPfizer, Inc. | 36 | 8 | $162.2B |
| 3 | GSKGSK plc | 34 | 11 | $100.9B |
| 4 | S SVASinovac Biotech, Ltd | 23 | 11 | $465M |
| 5 |  MRNAModerna, Inc. | 21 | 4 | $58.1B |
| 6 |  BNTXBioNTech SE | 16 | 4 | $26.2B |
| 7 | MRKMerck & Company, Inc. | 14 | 7 | $370.9B |
| 8 |  VALNValneva SE | 7 | 2 | $654M |
| 9 |  TAKTakeda Pharmaceutical Company Limited | 6 | 3 | $59.1B |
| 10 |  PCVXVaxcyte, Inc. | 4 | 3 | $9.1B |
CAR-T
245 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 |  DTILPrecision BioSciences, Inc. | 35 | — | $206M |
| 2 | NVSNovartis AG | 24 | 4 | $325.6B |
| 3 | BMYBristol-Myers Squibb Company | 24 | 5 | $136.5B |
| 4 |  GILDGilead Sciences, Inc. | 16 | 4 | $187.2B |
| 5 | AZNAstraZeneca PLC | 13 | 1 | $275.2B |
| 6 | JNJJohnson & Johnson | 12 | 2 | $663.3B |
| 7 |  KYTXKyverna Therapeutics, Inc. | 11 | — | $510M |
| 8 |  IOVAIovance Biotherapeutics, Inc. | 10 | 1 | $4.0B |
| 9 |  CABACabaletta Bio, Inc. | 6 | — | $588M |
| 10 |  AUTLAutolus Therapeutics plc | 6 | — | $596M |
Recombinant protein
188 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | IOVAIovance Biotherapeutics, Inc. | 11 | 1 | $4.0B |
| 2 |  IBRXImmunityBio, Inc. | 11 | 1 | $8.6B |
| 3 | PFEPfizer, Inc. | 10 | 6 | $162.2B |
| 4 | MRKMerck & Company, Inc. | 10 | 6 | $370.9B |
| 5 |  BMRNBioMarin Pharmaceutical Inc. | 10 | 3 | $12.9B |
| 6 | SNYSanofi | 10 | 3 | $106.9B |
| 7 | JNJJohnson & Johnson | 9 | 5 | $663.3B |
| 8 | AZNAstraZeneca PLC | 9 | 1 | $275.2B |
| 9 |  NVONovo Nordisk A/S | 8 | 1 | $158.0B |
| 10 | BMYBristol-Myers Squibb Company | 6 | 5 | $136.5B |
Gene therapy
184 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | NVSNovartis AG | 13 | 5 | $325.6B |
| 2 | MRKMerck & Company, Inc. | 10 | 5 | $370.9B |
| 3 |  SRPTSarepta Therapeutics, Inc. | 8 | 3 | $2.4B |
| 4 | ABBVAbbVie Inc. | 7 | 2 | $453.1B |
| 5 |  RAREUltragenyx Pharmaceutical Inc. | 7 | 3 | $1.5B |
| 6 |  CRSPCRISPR Therapeutics AG | 6 | — | $5.4B |
| 7 |  FDMT4D Molecular Therapeutics, Inc. | 6 | — | $783M |
| 8 | BMRNBioMarin Pharmaceutical Inc. | 5 | 1 | $12.9B |
| 9 |  ADVMAdverum Biotechnologies, Inc. | 5 | 2 | $96M |
| 10 |  RGNXREGENXBIO Inc. | 5 | 1 | $590M |
ADC
169 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | AZNAstraZeneca PLC | 47 | 17 | $275.2B |
| 2 | GILDGilead Sciences, Inc. | 18 | 7 | $187.2B |
| 3 | PFEPfizer, Inc. | 13 | 4 | $162.2B |
| 4 | BNTXBioNTech SE | 10 | 3 | $26.2B |
| 5 | ABBVAbbVie Inc. | 9 | 1 | $453.1B |
| 6 | MRKMerck & Company, Inc. | 9 | 4 | $370.9B |
| 7 |  ONCBeOne Medicines Ltd. | 7 | — | $39.3B |
| 8 | LLYEli Lilly and Company | 6 | 1 | $1.1T |
| 9 | GSKGSK plc | 5 | 3 | $100.9B |
| 10 |  BCYCBicycle Therapeutics plc | 4 | — | $217M |
Peptide
135 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | LLYEli Lilly and Company | 60 | 38 | $1.1T |
| 2 | NVONovo Nordisk A/S | 58 | 21 | $158.0B |
| 3 | REGNRegeneron Pharmaceuticals, Inc. | 2 | — | $83.7B |
| 4 | SNYSanofi | 2 | — | $106.9B |
| 5 |  IRTCiRhythm Holdings, Inc. | 1 | — | $4.0B |
| 6 |  VERUVeru Inc. | 1 | — | $45M |
| 7 |  VANIVivani Medical, Inc. | 1 | — | $128M |
| 8 |  GRCEGrace Therapeutics, Inc. | 1 | — | $44M |
| 9 |  ALNYAlnylam Pharmaceuticals, Inc. | 1 | — | $35.6B |
| 10 |  ARWRArrowhead Pharmaceuticals, Inc. | 1 | — | $12.2B |
Oligonucleotide
119 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | NVSNovartis AG | 29 | 15 | $325.6B |
| 2 | ALNYAlnylam Pharmaceuticals, Inc. | 16 | 4 | $35.6B |
| 3 |  BIIBBiogen Inc. | 14 | 6 | $32.6B |
| 4 |  IONSIonis Pharmaceuticals, Inc. | 11 | 9 | $9.7B |
| 5 | GSKGSK plc | 7 | 2 | $100.9B |
| 6 | AZNAstraZeneca PLC | 6 | 1 | $275.2B |
| 7 | REGNRegeneron Pharmaceuticals, Inc. | 5 | — | $83.7B |
| 8 |  WVEWave Life Sciences Ltd. | 4 | — | $935M |
| 9 | RAREUltragenyx Pharmaceutical Inc. | 3 | 2 | $1.5B |
| 10 |  VRTXVertex Pharmaceuticals Incorporated | 2 | — | $138.6B |
mRNA
89 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | MRNAModerna, Inc. | 37 | 4 | $58.1B |
| 2 | SNYSanofi | 8 | — | $106.9B |
| 3 | PFEPfizer, Inc. | 6 | — | $162.2B |
| 4 | BNTXBioNTech SE | 5 | 1 | $26.2B |
| 5 | MRKMerck & Company, Inc. | 5 | 2 | $370.9B |
| 6 | GSKGSK plc | 4 | — | $100.9B |
| 7 |  RNACCartesian Therapeutics, Inc. | 2 | 1 | $280M |
| 8 |  BEAMBeam Therapeutics Inc. | 2 | — | $3.1B |
| 9 |  ARCTArcturus Therapeutics Holdings Inc. | 2 | — | $450M |
| 10 | S SVASinovac Biotech, Ltd | 2 | — | $465M |
Radioconjugate
74 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | NVSNovartis AG | 38 | 5 | $325.6B |
| 2 |  TLXTelix Pharmaceuticals Limited | 6 | 4 | $4.1B |
| 3 | LLYEli Lilly and Company | 5 | 1 | $1.1T |
| 4 | BMYBristol-Myers Squibb Company | 4 | 1 | $136.5B |
| 5 | AZNAstraZeneca PLC | 3 | — | $275.2B |
| 6 |  LNTHLantheus Holdings, Inc. | 3 | 1 | $6.6B |
| 7 |  GEHCGE HealthCare Technologies Inc. | 3 | — | $31.1B |
| 8 | EXELExelixis, Inc. | 3 | — | $14.6B |
| 9 |  AKTSAktis Oncology, Inc. | 2 | — | $1.4B |
| 10 |  ACIUAC Immune SA | 2 | — | $291M |
Cell therapy
64 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | IOVAIovance Biotherapeutics, Inc. | 10 | 1 | $4.0B |
| 2 | INCYIncyte Corporation | 4 | — | $25.7B |
| 3 | TAKTakeda Pharmaceutical Company Limited | 4 | 2 | $59.1B |
| 4 | JNJJohnson & Johnson | 4 | 4 | $663.3B |
| 5 | SNYSanofi | 4 | — | $106.9B |
| 6 |  MGTXMeiraGTx Holdings plc | 2 | — | $1.3B |
| 7 | ONCBeOne Medicines Ltd. | 2 | — | $39.3B |
| 8 | IBRXImmunityBio, Inc. | 2 | — | $8.6B |
| 9 |  ATNMActinium Pharmaceuticals, Inc. (Delaware) | 2 | — | $32M |
| 10 | PFEPfizer, Inc. | 2 | 1 | $162.2B |
PROTAC
28 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | PFEPfizer, Inc. | 7 | 2 | $162.2B |
| 2 | ONCBeOne Medicines Ltd. | 4 | 2 | $39.3B |
| 3 |  KYMRKymera Therapeutics, Inc. | 3 | — | $9.8B |
| 4 |  ARVNArvinas, Inc. | 3 | — | $606M |
| 5 |  NRIXNurix Therapeutics, Inc. | 3 | — | $2.7B |
| 6 |  CCCCC4 Therapeutics, Inc. | 2 | — | $463M |
| 7 | NVSNovartis AG | 1 | — | $325.6B |
| 8 |  SLRXSalarius Pharmaceuticals, Inc. | 1 | — | $5M |
| 9 |  GLUEMonte Rosa Therapeutics, Inc. | 1 | — | $1.2B |
| 10 | BMYBristol-Myers Squibb Company | 1 | 1 | $136.5B |
Cancer vaccine
26 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | BNTXBioNTech SE | 3 | — | $26.2B |
| 2 | REGNRegeneron Pharmaceuticals, Inc. | 2 | — | $83.7B |
| 3 |  CADLCandel Therapeutics, Inc. | 2 | 1 | $978M |
| 4 | BMYBristol-Myers Squibb Company | 2 | — | $136.5B |
| 5 | PFEPfizer, Inc. | 1 | — | $162.2B |
| 6 |  IOBTIO Biotech, Inc. | 1 | — | $3M |
| 7 |  GOVXGeoVax Labs, Inc. | 1 | — | $4M |
| 8 |  EVAXEvaxion A/S | 1 | — | $26M |
| 9 | INCYIncyte Corporation | 1 | — | $25.7B |
| 10 |  BCTXBriaCell Therapeutics Corp. | 1 | — | $31M |
About this data: Modality classification is derived from ClinicalTrials.gov sponsor descriptions and intervention metadata. Coverage is currently strongest in Small Molecule, Monoclonal Antibody, and Gene Therapy - finer-grain modalities (ADC, bispecific, CAR-T, oligonucleotide, peptide) are being added in upcoming releases. Companies with fewer than 10 upcoming trials in a modality are not ranked.